Ovarian cancer is often fatal and is generally diagnosed only after significant tumor progression. Five-year survival is less than 50%. In the United States, over 225,000 women have ovarian cancer.
Aldeyra’s chaperome inhibitors, in combination with DNA-damaging agents, may have utility in the treatment of certain cancers. The chaperome inhibitor system is required for DNA repair, and chaperome inhibition in the setting of DNA damage could lead to cancer cell death. In ovarian cancer cell lines, preclinical studies have demonstrated the anti-proliferative synergy of ADX-1612 in combination with platinum-containing DNA damaging agents*
*Kramer, Daniela et al. “Strong antitumor synergy between DNA crosslinking and HSP90 inhibition causes massive premitotic DNA fragmentation in ovarian cancer cells.” Cell death and differentiation vol. 24,2 (2017): 300-316. doi:10.1038/cdd.2016.124